Abstract
This study aimed to investigate the cost-effectiveness of dapagliflozin added to standard therapy vs. standard therapy only in the treatment of adult patients with chronic heart failure with reduced ejection fraction from the Turkish payer perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
